The Patent License Your Startup Is Building On Was Never Actually Validated

Most technical founders treat a patent license from their university like a deed to a house. You paid the fees, you signed the papers, you have the right to build. What you actually have is a promise to enforce rights that nobody has tested, on claims that may not cover what you're actually selling, from an institution that reserved the right to license the same technology to someone else.

Photo by RDNE Stock project on Pexels.

That's the starting point. Things get more complicated from there.

The Difference Between a Patent and a Patent That Holds Up

A granted patent is not a validated patent. It's an administrative act by a government agency working through a backlog with limited time per application. Examiners miss prior art. Claims get written broad to survive prosecution and then collapse in litigation. The USPTO grants plenty of patents that would never survive an inter partes review challenge, and sophisticated acquirers and their counsel know this.

When a strategic acquirer or serious institutional investor sees your IP section, their legal team is not asking "do you have patents?" They're asking whether your claims are defensible, whether they cover your actual product, and whether the prosecution history created any damaging statements that would narrow the claims in court. Three very different questions. Most founders can't answer any of them.

Your university tech transfer office almost certainly cannot answer them either.

What University Licenses Actually Transfer

Read the license agreement carefully, specifically the definition of "licensed patents." In many university agreements, this covers only the specific patent applications listed in Exhibit A at signing. Continuation applications, divisionals, and related filings may or may not be included depending on the language, and universities have quietly licensed overlapping IP to other parties when the claims were distinct enough to justify it legally.

The field of use restriction is where founders get trapped most often. Universities carve fields of use to maximize their licensing revenue across multiple parties. Your license may cover cardiovascular applications while a competitor in oncology holds rights to the same core technology. If your product pivots, you may find yourself outside your licensed field without knowing it.

Government funding adds another layer. If any federal money touched the research that generated your licensed IP, the Bayh-Dole Act gives the U.S. government march-in rights. In practice, march-in has rarely been exercised, but the rights exist, and they live in your cap table whether you disclosed them to investors or not.

Why Investors Find This Later Than You'd Like

Seed investors often don't run serious IP diligence. They're moving fast, trusting the founder, and betting on the team. Series A investors start asking questions. Series B investors hire outside IP counsel. Strategic acquirers bring in dedicated IP litigation firms.

The pattern plays out like this:

graph TD
    A[Founder licenses university patent] --> B(Builds product, raises seed)
    B --> C(Series A diligence: claims reviewed)
    C --> D{Claims cover product?}
    D --> E[Yes: proceed normally]
    D --> F[No: renegotiate license or redesign]
    F --> G((Deal delay or valuation haircut))

By the time the problem surfaces in a Series A or acquirer process, you've built a product around IP assumptions that turn out to be wrong. Renegotiating a license mid-fundraise is a negotiation where you have zero leverage. The university knows exactly what the deal means to you.

What to Actually Do About It

Get an independent freedom-to-operate opinion before you close your seed round. Not from your university's general counsel, not from the IP attorney your advisor recommended without checking their credentials. From a firm that does IP litigation, because FTO opinions from litigators read differently than those from prosecution-only counsel.

Pay attention to the claims chart. Your product needs to be mapped to specific claims in your licensed patents, and you need to understand which claims would actually be infringed by a competitor making your thing. Broad claims that sound impressive in a pitch deck are often the ones that collapse first.

Ask your tech transfer office directly: has any other party received a license to any of the patents in Exhibit A, or to any related applications? Get the answer in writing. The answer being "no" is genuinely useful. The answer being evasive tells you something important.

If you discover the claims don't cleanly cover your product, you have two options: file continuation applications on the specific implementations you've developed (assuming the original disclosure supports them), or start building a trade secret strategy around your manufacturing process and know-how. Patents that don't cover your product aren't worthless, but they're not a moat. Trade secrets require discipline and documentation from day one.

The uncomfortable truth is that most deep tech startups are sitting on IP positions that haven't been stress-tested. That's survivable if you find out early. Finding out during acquisition diligence, when the buyer's counsel is already skeptical of everything, is where deals die quietly.